Inyx Inc

Inyx Inc
825 3rd Ave Fl 40
NEW YORK NY 10022-7592
P: +1212.8381111
F: +1212.8380060

Jack Kachkar, 45, Chairman of the Board, Chief Executive Officer
Steven Handley, 49, 2007, President
Colin Hunter, 55, 2007, Executive Vice President, Chief Scientific Officer
Jay Green, 62, 2007, Executive Vice President and Director of Corporate Development, Director
Stephen Beckman, 45, Vice President of Sales and Marketing and Commercial Development
William Kelly, 2006, Vice President of Investor Relations & Corporate Communications

Jack Kachkar
Dr. Kachkar is a medical doctor with experience as an executive within the pharmaceutical industry. Dr. Kachkar has founded and assisted in the acquisition of a number of pharmaceutical companies focused on niche product development and manufacturing capabilities. He has also provided consulting and advisory services within the pharmaceutical industry and was a founder in 1995 of a medical publishing company. In addition to his role as Chairman of the Board and Chief Executive Officer of Inyx, Dr. Kachkar is also currently the Chairman and Chief Executive of Karver International, Inc., a publicly-held health care services company. From 1996 until December 2002, Dr. Kachkar was President and CEO of Miza Pharmaceuticals, Inc. (“Miza”), a Canadian corporation in Toronto, Ontario. Miza is now inactive. While in operation, Miza had three operating subsidiaries, Miza Pharmaceuticals (UK), Ltd. (“Miza UK”), Miza Ireland Limited (“Miza Ireland”) and Miza Pharmaceuticals USA, Inc. (“Miza USA”). Dr. Kachkar was involved in the management of all four companies, although he resigned as an officer of Miza in December 2002 and as a director in May 2003, prior to that company becoming inactive; he resigned as a director of Miza UK in August 2002 and was never an officer; he resigned as a director of Miza Ireland in October 2002 and was never an officer; and he resigned as an officer of Miza USA in March 2003 and as a director in April 2003. Miza UK was placed in Administration in September, 2002 and sold its assets out of Administration in March 2003 to Inyx Pharma; Miza Ireland’s assets were sold by a court-appointed liquidator during 2003; Miza USA was placed into Chapter 11 bankruptcy proceedings by its new owners in May 2003 under the name Carr Pharmaceuticals, Inc., and was then subsequently liquidated by its secured lenders. Dr. Kachkar earned his medical degree summa cum laude in 1995 from the English Language Medical Program at Semmelweis Medical University in Budapest, Hungary.

Steven Handley
Mr. Handley has over 20 years experience within the pharmaceutical industry. During this period, Mr. Handley has held several senior management positions in manufacturing and technical operations. He has extensive experience in the development and manufacture of sterile pharmaceuticals and aerosols technology. Mr. Handley has worked for Evans Medical, Medeva PLC, and, during the past five years for CCL Pharmaceuticals and its successor Miza UK, where he was responsible for all manufacturing and technical operations as Senior Vice President. Mr. Handley holds a qualified pharmaceutical technician degree and is a member of several professional bodies. He also holds a diploma in management and is experienced in vaccine manufacturing and lyophilization technology.

Colin Hunter
Mr. Hunter has over 25 years experience within the pharmaceutical industry where he has held senior positions within quality and manufacturing operations, gaining extensive experience of regulatory authorities’ requirements for pharmaceutical products, including both FDA and EU regulatory agencies. During his career, he has worked for Glaxo Pharmaceuticals, Evans Medical Ltd. and Medeva PLC. From January 1990 until June 2000, he was European Quality Director for Medeva Pharma Ltd., a subsidiary of Medeva + Celltech PLC. From July 2000 until April 2001, he was Quality Director for CCL Industries, Inc. From May 2001 until February 2003, he was Senior Vice President of Miza Pharmaceuticals UK, Ltd. From March 2003 until April 2003, he was a director of Inyx Pharma Limited, and he became Executive Vice President of the Company in May 2003. Mr. Hunter holds a Bachelor of Science Degree with Honors in Bacteriology and Virology. He is a Chartered Biologist, Member of the Institute of Biology, a Fellow of The Institute of Quality Assurance and is a member of other professional societies.

Jay Green
Mr. Green joined Inyx in December 2003. From January until November 2003, Mr. Green was a managing director of Duncan Capital, LLC, a merchant banking/investment banking firm that served as the investment banking firm. From June 2001 until 2002 year-end, Mr. Green was a Managing Director of BlueFire Partners, a Minneapolis-based capital markets advisory firm. From January 2001 until May 2001, Mr. Green served as an independent financial consultant advising both private and public companies. From June 2000 until December 2000, he was a Vice President with Unapix Entertainment, Inc., which was a public company on the American Stock Exchange (ASE: UPX) that filed for bankruptcy and its assets were subsequently liquidated. From March 1999 to May 2000, Mr. Green was an independent consultant advising private and public companies. From September 1998 until February 1999, he served as a Vice President with Paxar Corp. (NYSE: PXR). From January 1991 until May 1998, Mr. Green was a Vice President with Seitel, Inc. (which was on the ASE and then the NYSE during his tenure).

Stephen Beckman
Mr. Beckman joined Inyx in September 2005. Prior to joining Inyx, Mr. Beckman served as a consultant to the pharmaceutical industry. Earlier, he served as Corporate Vice President of Global Franchise Management and Vice President of Corporate Marketing, Respiratory for Altana Pharma AG. He was also Worldwide Director - Pulmonary Marketing for SmithKline Beecham Pharmaceuticals. Mr. Beckman has held executive marketing positions also with Astra Merck Corporation and Fisons Pharmaceutical Corporation, and he began his career with Marion Merrell Dow Pharmaceuticals. Mr. Beckman holds a B.S. in Marketing from Syracuse University and graduate studies in pharmaceutical marketing from UCLA and advanced studies at the Wharton School of Business.

William Kelly
Mr. Kelly has more than 20 years of experience in investor relations and corporate communications, which includes working with multinational companies. Prior to joining Inyx, Mr. Kelly was a consultant for more than ten years, advising a range of Nasdaq and New York Stock Exchange-listed companies, such as Taro Pharmaceuticals, Cytec Industries and BET plc as well as the accounting firm KPMG. Earlier, he was a full-time consultant to Bristol-Myers Squibb, and he served as a Vice President with J.P. Morgan & Co. Mr. Kelly is a graduate of Princeton University and has a MBA from Rutgers University.

Inyx, Inc. is a provider of specialty pharmaceutical products and technologies. Its operations are focused on the development of both prescriptions, over the counter pharmaceutical products, and specialty consulting services. Also, the Company utilizes niche drug delivery capabilities to develop its own products. The product and service categories of the Company include Metered Dose Inhalers (MDIs) (CFC & HFA), Dry Powder Inhalers (DPIs), Metered Dose Pump Sprays (nasal and oral), Hydrocarbon Foam Aerosols, Saline Aerosols, Sterile Solutions/Injectables, Solid Dose, Formulation Services, Analytical Development Validation, Stability Services, Regulatory Support and Integrated Project Management.

In the Metered Dose Inhalers (MDIs) (CFC & HFA) category, the Company manufactures MDIs employing both chlorofluorocarbon (CFC) and hydrofluroalkane (HFA) propellant technologies. The HFA products developed by the Company include Metered Dose Inhalers for respiratory ailments and Metered Dose Oral Spray for cardiac ailments. The DPI products are used in the treatment of respiratory ailments such as asthma. It is also utilized in insulin for diabetes, pain management drugs and other systemic diseases.

The Metered Dose Pump sprays (nasal and oral) are used in the treatment of nasal decongestion, anti-allergic and anti-inflammatory applications. These sprays manufactured are used ideally for complex proteins and pain medications. In the Hydrocarbon Foam Aerosols category, the Company manufactures hydrocarbon aerosols as a delivery system for dermatological and topical drug applications. In the Saline Aerosols category, the Company manufactures products, which are nitrogen propelled buffered and non-buffered normal saline aerosols for eye and wound care, Water-For-Injection (WFI)/alcohol aerosols and non-alcohol based disinfectant aerosols.

The Sterile solutions, the Company is able to produce up to 40 million units per annum. It manufactures in batch sizes from sub one liter through to 200 liters, ampoules, vials and ophthalmics in a variety of fill volumes. It also offers automated packaging lines for the range of presentations. In the Solid dose category, the Company produces up to two billion tablets and capsules. These products developed are by way of a contained granulation process for both solvent and aqueous formulations and the computer controlled compression machines are capable of producing up to 200,000 tablets per hour. The company provides services, such as Formulation Services, Analytical Development and Validation, Stability Services, Regulatory Support and Integrated Project Management services.

The company distributes its products through subsidiaries. Its products are marketed through collaboration agreement with industry partners. The company holds five wholly owned subsidiaries, namely, Inyx USA, Ltd., Manati, Puerto Rico; Inyx Pharma Limited, Cheshire; Ashton Pharmaceuticals Limited, Ashton; Inyx Canada Inc., Ontario, and Exaeris, Inc., Pennsylvania.

The Company competes with Albany Molecular Research Inc., Genentech Inc. and PAREXEL International Corporation.